Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey

Autor: Tingting Zhang, Chao Meng, Wei He, Tao Xu, Yi Yang, Chongqi Tu, Ling Zhang, Xiaofeng Sun, Chunrong Zhu, Xueyi Dang, Ke Wang, Chuan Chen, Xiong Yan, Huiting Xu, Le Huang, Enlai Jiang, Feng Xia, Xinming Zhou, Shunkai Zhou, Weidong Zang, Xifeng Li, Jin Zhang, Jiaping Zheng, Jianjun Xin, Bin Huang, Guopei Zhu, Jiexiang Zhu, Jun Liang
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Druh dokumentu: article
ISSN: 1471-2407
DOI: 10.1186/s12885-024-12832-3
Popis: Abstract Background Data on long-term cancer survivors treated with apatinib are lacking. This study aimed to describe the characteristics of long-term cancer survivors after apatinib-based therapy, and to know about their satisfaction degree with apatinib and severity of depression and insomnia. Methods Patients with solid tumors who had received apatinib-based therapy for at least 5 years were invited to complete an online questionnaire. Characteristics of patients and treatment, knowledge of apatinib, satisfaction degree, and severity of depression and insomnia assessed by Patient Health Questionnaire-9 and Insomnia Severity Index were collected. Results Between December 8, 2023 and March 1, 2024, a total of 436 patients completed the online questionnaire. Most patients were satisfied with the efficacy (96.6%) and safety (93.1%) of apatinib, were willing to continue apatinib treatment (99.5%), and would recommend apatinib to other patients (93.3%). Continuous apatinib treatment resulted in significant negative impact on daily life, work, or study in only two (0.5%) patients. Almost all patients currently had no or mild depression (97.0%) and insomnia (97.9%) problems. The most common patient-reported adverse events were hand-foot syndrome (21.3%) and hypertension (18.3%). Conclusions Our survey showed a high satisfaction degree with apatinib in long-term cancer survivors. Long-term apatinib treatment resulted in almost no negative impact on patient’s quality of life.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje